This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claim 1 (currently amended): A method for lowering sex hormone levels in ~~an individual~~ **a human subject in need of treatment**, comprising administering to ~~an individual appropriate doses~~ **the subject an effective amount** of an LHRH-antagonist, **wherein said LHRH-antagonist is** peptidic or non-peptidic, ~~wherein~~ **and said LHRH-antagonist will lower** sex hormone levels ~~in said individual are lowered to a certain extent~~ but not **to the point of castration or** below the castration level of said ~~individual~~ **subject**.

Claim 2 (currently amended): A method for lowering sex hormone levels in ~~an individual~~ **a human subject in need of treatment**, comprising administering ~~appropriate doses~~ **to the subject an effective amount** of an LHRH-antagonist to ~~an individual~~ **said subject** wherein the lowered sex hormone levels in said ~~individual~~ **subject** result in modification of the T-cell population in said ~~individual~~ **subject**.

Claim 3 (canceled).

Claim 4 (currently amended): A method for lowering sex hormone levels in ~~an individual~~ **a human subject in need of treatment**, comprising administering ~~appropriate doses~~ **to the subject an effective amount** of an LHRH-antagonist to ~~an individual~~ **said subject**

wherein the lowered sex hormone levels in said ~~individual~~ **subject** result in a modification of the T-cell population in an individual suffering from a HIV infection, cancer, an auto-immune disease, ~~benign prostatic hyperplasia~~, endometriosis, asthma, arthritis, dermatitis, multiple sclerosis, Jacob Creuzfeldt-disease, or Alzheimer's disease.

Claim 5 (canceled).

Claim 6 (canceled).

Claim 7-11 (withdrawn).

Claim 12 (Currently amended): The method according to any one of claims 1-6, wherein ~~the~~ **said** LHRH-antagonist is chosen from ~~cetrorelix, teverelix, antide, or abarelix~~ **CETRORELIX, TEVERELIX, ANTIDE, or ABARELIX.**

Claim 13 (Currently amended): The method according to any one of claims 1-6, wherein ~~the~~ **said** LHRH-antagonists is ~~cetrorelix~~ **CETRORELIX** or a pharmaceutically acceptable salt form thereof.

Claim 14 (currently amended): The method according to any one of claims 1-6, wherein ~~the appropriate doses~~ **said effective amount** of an LHRH-antagonist ~~are determined from a total dosage range of~~ **is administered at a dose of about** 5 mg to 120 mg ~~divided in~~ **for** a period ~~of~~ **ranging from** 1 to 8 weeks ~~according to needs of the individual with repeat of the therapy every 3 to 4 months~~ **and optionally repeating method of lowering sex hormone levels every 3 to 4 months while there is still a need of treatment by said subject**.

Claim 15 (currently amended): The method according to any one of claims 1-6, wherein the LHRH-antagonist ~~cetrorelix pamoate~~ **CETRORELIX PAMOATE** is administered ~~in a dosage amount determined from a total dosage range of~~ **at a dose of about** 30 mg to 120 mg ~~divided in~~ **for** a period ~~of~~ **ranging from** 1 to 4 weeks ~~according to needs, with repeat of the therapy method every 3 to 4 months as needed~~ **and optionally repeating method of lowering sex hormone levels every 3 to 4 months while there is still a need of treatment by said subject**

Claim 16 (currently amended): The method according to any one of claims 1-6, wherein the LHRH-antagonist ~~cetrorelix acetate~~ **CETRORELIX ACETATE** is administered ~~in a dosage amount determined from a total dosage range of~~ **in a dose of about** 5 mg to 80 mg ~~divided in~~ **for** a period ~~of~~ **ranging from** 1 to 8 weeks ~~according to needs, with repeat of the therapy method every 3 to 4 months as needed~~ **and optionally repeating method of lowering sex hormone levels every 3 to 4 months while there is still a need of treatment by said subject**.